Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1614 1618
This examiner grants 41% of resolved cases
Jake Minh Vu works in Tech Center 1600 and Art Unit 1614. The examiner has 806 resolved cases. The allowance rate is 41.1 percent. This indicates a challenging environment for applicants, as a minority of resolved cases result in a grant. Practitioners should be prepared for a rigorous examination process and a potentially difficult path to allowance.
The interview lift is 27.2 percent. This significant lift suggests that interviews are a very effective way to improve the 41.1 percent allowance rate. Practitioners should prioritize interviews to advance their applications and resolve outstanding issues. The data shows that direct communication is a valuable strategy for overcoming rejections in Art Unit 1614.
The median days to allowance is 1519. This is a relatively long pendency for applications that result in a grant. With 806 resolved cases, the data provides a clear picture of the examiner's performance in Tech Center 1600. This timeline is an important consideration for applicants when planning their intellectual property strategy and managing expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18917556 | BIODEGRADABLE DRUG ELUTING MICROSPHERE FOR THE TREATMENT OF SOLID TUMORS | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18267136 | INSTANTLY GELLING COMPOSITIONS FOR ARTIFICIAL SALIVA AND ULTRASOUND GELS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18310796 | METHODS FOR TREATING SHORT BOWEL SYNDROME AND/OR HIGH OUTPUT OSTOMY | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 18397190 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | Non-Final OA | BIOGEN MA INC. |
| 17786403 | RED BLOOD CELL-DERIVED VESICLE | Final Rejection | Imperial College Innovations Limited |
| 16641059 | SLIPPERY MICROPROPELLERS PENETRATE THE VITREOUS HUMOR | Final Rejection | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18010216 | ULTRASOUND-SENSITIVE BIODEGRADEABLE MULTI-CAVITY MICRO-PARTICLES | Final Rejection | OXFORD UNIVERSITY INNOVATION LIMITED |
| 17414414 | INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS | Non-Final OA | Cornell University |
| 17294368 | LIQUIDLY INJECTABLE, SELF-STABILIZING BIOPOLYMERS FOR THE DELIVERY OF RADIONUCLIDE | Non-Final OA | Duke University |
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | Final Rejection | MICROVASCULAR THERAPEUTICS, LLC |
| 18034551 | RADIOLABELED ETHER DENDRIMER CONJUGATES FOR PET IMAGING AND RADIOTHERAPY | Non-Final OA | Programmable Medicine Operating Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy